Trial Profile
INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Stroke; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms INVICTUS-VKA
- 03 Oct 2022 Status changed from active, no longer recruiting to completed.
- 28 Aug 2022 Results published in the New England Journal of Medicine
- 14 Jul 2022 Planned End Date changed from 1 Aug 2022 to 31 Jul 2022.